| Old Articles: <Older 6811-6820 Newer> |
|---|
 |
The Motley Fool
October 22, 2010
Luke Timmerman |
Aastrom Maps Out Pivotal Trial Strategy With Adult Stem Cell Therapy Aastrom needs a good strategy for working with U.S. drug regulators.   |
The Motley Fool
October 21, 2010
Moser & Hinmon |
DRIP Candidate Winner: Becton, Dickinson In a health-care bloodbath, Becton, Dickinson pounds Walgreen to a pulp. |
The Motley Fool
October 21, 2010
Anand Chokkavelu |
6 Health-Care Stocks Near 52-Week Lows Here are the largest health care equipment and services companies (by market cap) that are hugging 52-week lows: Medtronic... Covidien... Stryker... Becton, Dickinson and Company... McKesson... Cardinal Health... |
The Motley Fool
October 21, 2010
Seth Jayson |
From Gross to Net at GlaxoSmithKline Here's the current margin snapshot for GlaxoSmithKline and some of its sector and industry peers and direct competitors. |
The Motley Fool
October 21, 2010
Brian Orelli |
Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason. |
The Motley Fool
October 21, 2010
Brian Orelli |
Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track. |
The Motley Fool
October 21, 2010
Brian Orelli |
Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors. |
Fast Company
November 2010
Elizabeth Svoboda |
The Myelin Repair Foundation Encourages Collaboration for a Cure Scientists in their labs. Big Pharma in pursuit of the next blockbuster. An innovative foundation brings them together to speed up the discovery of multiple-sclerosis drugs. |
The Motley Fool
October 20, 2010
Matt Koppenheffer |
Neurocrine Biosciences Shares Popped: What You Need to Know Shares of biotech Neurocrine Biosciences were up more than 10% in intraday trading on higher-than-average volume. |
The Motley Fool
October 20, 2010
Seth Jayson |
Checking for Revenue Tricks at IDEXX Labs Is IDEXX Laboratories sending any potential warning signs? |
| <Older 6811-6820 Newer> Return to current articles. |
